Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Change in Cash (2016 - 2025)

Historic Change in Cash for Intellia Therapeutics (NTLA) over the last 11 years, with Q3 2025 value amounting to $37.2 million.

  • Intellia Therapeutics' Change in Cash rose 45944.56% to $37.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $73.2 million, marking a year-over-year increase of 25621.96%. This contributed to the annual value of -$37.6 million for FY2024, which is 8727.05% up from last year.
  • According to the latest figures from Q3 2025, Intellia Therapeutics' Change in Cash is $37.2 million, which was up 45944.56% from $21.9 million recorded in Q2 2025.
  • Intellia Therapeutics' 5-year Change in Cash high stood at $385.7 million for Q4 2022, and its period low was -$229.4 million during Q1 2023.
  • For the 5-year period, Intellia Therapeutics' Change in Cash averaged around $2.2 million, with its median value being -$6.9 million (2022).
  • As far as peak fluctuations go, Intellia Therapeutics' Change in Cash crashed by 162984.93% in 2023, and later skyrocketed by 45944.56% in 2025.
  • Over the past 5 years, Intellia Therapeutics' Change in Cash (Quarter) stood at -$211.5 million in 2021, then surged by 282.4% to $385.7 million in 2022, then crashed by 84.61% to $59.4 million in 2023, then increased by 15.7% to $68.7 million in 2024, then plummeted by 45.82% to $37.2 million in 2025.
  • Its Change in Cash stands at $37.2 million for Q3 2025, versus $21.9 million for Q2 2025 and -$54.6 million for Q1 2025.